Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 6/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | CENPE | Q02224 | 1/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6217165 | 0.99 | S1PR1 (0.42) | S1PR1MEN1KMT2AP2RX3TP53 | |
| SCHEMBL6763926 | 0.97 | MEN1 (0.42) | S1PR1MEN1KMT2AP2RX3TP53 | |
| SCHEMBL6216612 | 0.94 | P2RX3 (0.45) | S1PR1MEN1KMT2AP2RX3TP53 | |
| SCHEMBL6213796 | 0.91 | ACHE (0.43) | ACHE | |
| SCHEMBL6213972 | 0.91 | ACHE (0.44) | ACHE | |
| SCHEMBL6219168 | 0.90 | PDE5A (0.38) | KMT2AP2RX3TP53ACHE | |
| SCHEMBL6215433 | 0.89 | PDE5A (0.38) | KMT2AP2RX3TP53ACHE | |
| SCHEMBL6214624 | 0.89 | FFAR1 (0.42) | — | |
| SCHEMBL6762884 | 0.88 | ACHE (0.45) | ACHE | |
| SCHEMBL6219232 | 0.88 | FFAR1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084125-B1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 2005-12-28 | — | — | EP | disclosed |
| EP-1259229-B1 | USE OF BENZO-THIENO[2,3-d]PYRIMIDINES HAVING PDE V INHIBITING ACTIVITY FOR THE TREATMENT OF ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | MERCK PATENT GMBH (DE) | 2004-04-01 | — | — | US | disclosed |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | MERCK PATENT GMBH (DE) | 2004-03-25 | — | — | US | disclosed |
| EP-1357915-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2003-11-05 | — | — | EP | disclosed |
| EP-1347762-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GmbH (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030022906-A1 | Use of pde v inhibitors | MERCK PATENT GMBH (DE) | 2003-01-30 | — | — | US | disclosed |
| US-6495557-B1 | SUCH AS 3-(4-(3-CHLORO-4-METHOXYBENZYLAMINO)BENZO-(4,5)-THIENO (2,3-D)PYRIMIDIN-2-YL)PROPIONIC ACID; CARDIOVASCULAR DISORDERS AND/OR IMPAIRED POTENCY | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2002-12-17 | — | — | US | disclosed |
| EP-1259229-A2 | USE OF PDE V INHIBITORS | MERCK PATENT GmbH (DE) | 2002-11-27 | — | — | EP | disclosed |
| WO-2002062343-A2 | PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO[4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2002-08-15 | — | — | WO | disclosed |
| WO-2002049649-A2 | PHARMACEUTICAL FORMULATION CONTAINING THIENOPYRIMIDINES AND ANTITHROMBOTICS, CALCIUM ANTAGONISTS, PROSTAGLANDINS OR PROSTAGLANDIN DERIVATIVES (2) | MERCK PATENT GMBH (DE) | 2002-06-27 | — | — | WO | disclosed |
| EP-1212062-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GmbH (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001064192-A2 | USE OF BENZOTHIENO-2,3-D-PYRIMIDINES WITH PDE V INHIBITORY EFFECT FOR THE TREATMENT OF ERECTILE DYSFUNCTION | MERCK PATENT GMBH (DE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2001019369-A1 | USE OF THIENOPYRIMIDINES | MERCK PATENT GMBH (DE) | 2001-03-22 | — | — | WO | disclosed |
| EP-1084125-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GmbH (DE) | 2001-03-21 | — | — | EP | disclosed |
| WO-1999055708-A1 | CONDENSED THIENOPYRIMIDINES WITH PHOSPHODIESTERASE-V INHIBITING ACTION | MERCK PATENT GMBH (DE) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077664-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidine and nitrates or thienopyrimidines and nitrates | PTGIS, DPYD, PTGIR | S1PR1 1727/4885MEN1 3785/4885KMT2A 4595/4885 |
| US-20040063731-A1 | Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists | EDNRA, EDNRB, PTGIR | S1PR1 325/4885MEN1 3633/4885KMT2A 4594/4885 |
| US-20040058940-A1 | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) | PTGER1, PTGIS, PTGIR | S1PR1 171/4885MEN1 1895/4885KMT2A 4746/4885 |
| US-20030022906-A1 | Use of pde v inhibitors | PDE3A, PDE5A, PDE2A | S1PR1 895/4885MEN1 3082/4885KMT2A 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.